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Hepatitis C virus (HCV) infection can result in viral
chronicity or clearance. Although host genetics and
particularly genetic variation in the interferon lambda
(IFNL) locus are associated with spontaneous HCV
clearance and treatment success, the mechanisms
guiding these clinical outcomes remain unknown.
Using a laser capture microdissection-driven unbi-
ased systems virology approach, we isolated and
transcriptionally profiled HCV-infected and adjacent
primary human hepatocytes (PHHs) approaching
single-cell resolution. An innate antiviral immune
signature dominated the transcriptional response
but differed in magnitude and diversity between
HCV-infected and adjacent cells. Molecular signa-
tures associated with more effective antiviral control
were determined by comparing donors with high and
low infection frequencies. Cells from donors with
clinically unfavorable IFNL genotypes were infected
at a greater frequency and exhibited dampened anti-
viral and cell death responses. These data suggest
that early virus-host interactions, particularly host
genetics and induction of innate immunity, critically
determine the outcome of HCV infection.
INTRODUCTION
The majority of people infected with hepatitis C virus (HCV)
develop chronic infection, which can remain asymptomatic for
many years, ultimately leading to the development of liver
fibrosis, cirrhosis, and hepatocellular carcinoma (Alter and Liang,
2012; Brown, 2005). Interestingly, 20%–30% of people infected
with HCV are able to clear the infection and do not progress to
chronicity (Thomas et al., 2009). The molecular mechanisms
driving this clinical dichotomy remain unknown, in part because
of challenges in studying HCV in its native environment, the
human hepatocyte in the liver. Low levels of HCV replication
and antigen in infected hepatocytes have hampered the identifi-190 Cell Host & Microbe 15, 190–202, February 12, 2014 ª2014 Elsecation and isolation of infected cells by antibody staining (Liang
et al., 2009). Thus, the transcriptional response to HCV in an in-
fected hepatocyte in patients is not known. Exploring this host
response may reveal key pathways that influence clearance
versus chronicity and uncover new avenues for enhancing treat-
ment success.
Systems virology approaches generate unbiased data sets,
which can be mined to obtain more comprehensive views of
virus-host interactions. Initial systems approaches for HCV uti-
lized liver biopsy tissue from infected humans or chimpanzees
in which a minority of hepatocytes was infected (estimated
7%–20%) (Bigger et al., 2001, 2004; Liang et al., 2009; Sara-
sin-Filipowicz et al., 2008; Su et al., 2002). Thus, the transcrip-
tional response in an HCV-infected cell population could not
be separated from signals originating from uninfected hepato-
cytes and other liver cell types. Given the challenges of studying
HCV-infected hepatocytes in vivo, cultures of primary human
hepatocytes (PHHs) offer an attractive alternative. Like native
hepatocytes in the liver, PHHs are polarized, largely terminally
differentiated, and can robustly upregulate the innate immune
response upon infection (Andrus et al., 2011; Dill et al., 2012;
Jilg et al., 2013; Marukian et al., 2011; Metz et al., 2012; Park
et al., 2012; Thomas et al., 2012). However, mimicking HCV
infection in vivo, PHH infection frequency (2%–30%) and the
levels of virus replication are low, preventing viral antigen detec-
tion and isolation of uniformly infected cells (Andrus et al., 2011;
Liang et al., 2009; Ploss et al., 2010).
In the current study, we have overcome these challenges and
succeeded in defining the transcriptional response in HCV-
infected hepatocytes nearing single-cell resolution. We coupled
an HCV infection-dependent fluorescence relocalization (HDFR)
reporter (Jones et al., 2010) with laser capture microdissection
(LCM) (Espina et al., 2006) to isolate infected and adjacent cells.
An antiviral immune signature dominated the transcriptional
response but differed in HCV-infected and adjacent cells. By
comparing and contrasting data from donors with high and
low infection frequencies, we determined the signatures associ-
ated with effective antiviral control. In HCV-infected patients,
genetic variations at the interferon lambda (IFNL) locus exert a
profound effect on spontaneous viral clearance and treatment
success (Ge et al., 2009; Heim, 2013; Thomas et al., 2009).
We found that hepatocytes from donors with clinically lessvier Inc.
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and C/T) were more permissive for HCV infection compared
to cells from donors with favorable alleles (IFNL3 rs12979860,
major allele C/C). Although the antiviral program was not
absent in donors with IFNL minor alleles, responses were
neither uniform nor robust. These results highlight the power
of studying viral infection in disparate genetic backgrounds
and reveal a remarkable convergence with clinical findings.
Overall, our study suggests that early virus-host interactions,
in particular host genetics and the induction of innate antiviral
immunity, play a critical role in determining the outcome of
HCV infection.
RESULTS
Isolation of HCV-Infected PHH by LCM
PHH cultures were created from fetal liver of similar gestational
age and were similarly differentiated (Figure S1 available online).
We employed a fluorescent cellular reporter system (i.e., HDFR;
Figure 1A) to identify productively infected cells and isolate small
numbers (30 cells in quadruplicate) ofmock-infected cells (HFDR
expressing, HCV naive), HCV-infected cells (HDFR positive,
nuclear RFP), or cells adjacent to infected cells (adjacent cells,
HDFR expressing, perinuclear RFP; Figure 1C) via LCM (Fig-
ure 1B). HDFR is sensitive and requires active HCV replication
for efficient cleavage of the mitochondrial-localized RFP re-
porter, which then accumulates in the nucleus (Figure S2).
Importantly, LCM of discrete populations within a mixed culture
yielded minimal cross-contamination of transcriptomes, even
when in direct contact (Figure S3). Captured cell lysates were
divided for whole transcriptome analysis (20 cells) and qRT-
PCR (10 cells) to quantitate HCV genomes in each sample (Fig-
ure 1D). As confirmation, sequential photographs were taken
throughout the LCM process (Figure 1E). Cells positive for
HDFR harbored significantly more HCV genomes than adjacent
or mock-infected cells, even though adjacent cells were
exposed to high titers of HCV during infection (Figure 1F). These
data demonstrate that HDFR and LCM can be used successfully
to identify and isolate HCV-infected PHH. For HCV-infected
cells, the average number of HCV genomes/cell decreased
over time, suggestive of viral clearance. To more carefully
examine the kinetics of infection, infectious virus released into
the culture medium and infection frequency (Figure 2A) were
measured over time. While virus production was significantly
reduced between 1 and 3 days postinfection (dpi), select donors
secreted high titers of virus as late as 7 dpi. Similarly, infection
frequency decreased significantly between 3 and 7 dpi, and
few donors sustained levels at 7 dpi nearing those achieved at
earlier times.
An Innate Antiviral Program Dominates the Host
Response to HCV Infection
To gain a systems-level understanding of the responses guiding
these virological phenotypes, we performed whole-genome
microarray on 188 amplified cDNA libraries generated from
LCM samples of mock, HCV-infected, and adjacent cells (Tables
S1 and S3). Quality control of the cDNA libraries is described in
Figure S4. We pooled time-matched samples of all donors to
elucidate donor-independent responses. Similar to the trendCell Host &observed for infection frequency, the number of genes signifi-
cantly regulated more than 2-fold over mock in HCV-infected
and adjacent cells increased from 1 to 3 dpi but decreased
significantly by 7 dpi (Figure 2B). Remarkably, over half of the
genes regulated on 1 dpi in HCV-infected and adjacent cells
were associated with innate antiviral immunity (Figure 2C) and
likely contributed to the precipitous drop in virus production be-
tween 1 and 3 dpi (Figure 2A). This response decreased over
time but still comprised between 15%–25% of the significantly
regulated gene signature on 3 and 7 dpi. Furthermore, type III
interferon induction was observed only in HCV-infected cells,
suggesting that this cascade might be perpetuating the antiviral
response throughout the culture (Figures S5 and 2D). Interest-
ingly, IFNL1 protein secretion was blocked in HCV-infected
cultures by adding a viral replicase inhibitor (20CMA). Thus,
IFNL1 secretion was dependent on HCV replication (Figure 2E).
Given HCV’s ability to establish chronic infection with multiple
mechanisms to subvert innate immune responses, these data
unexpectedly indicate that an antiviral program dominates the
HCV-induced transcriptional response at very early times after
infection.
Distinct Antiviral Programs in Infected and Adjacent
Cells
To examine possible differences between HCV-infected and
adjacent cells, gene ontology analyses were performed. Antiviral
responses in HCV-infected cells followed a distinct temporal
order comprised of three phases (Figure 2F). During the initial
phase, genes related to the induction of the innate immune
response were upregulated in HCV-infected cells (e.g., DDX58,
IRF7, STAT1, etc.) along with interferon-stimulated effector
genes (ISGs; e.g., IFIT1, OAS2, etc.), leukocyte-recruiting che-
mokines (CXCL10 and CCL5), and genes related to posttransla-
tional modification and regulation (e.g., ISG15, USP18, etc.).
During the second phase, expression of the inducers of innate
immunity had for the most part waned, but the expression of
effector ISGs (e.g.,DDX60, IFI27, IFITM1, etc.) and genes related
to antigen presentation (B2M, HLA-B, etc.) had increased. The
third ‘‘constitutive’’ phase was marked by antiviral genes that
were upregulated at all time points (e.g., BST2, HERC6, IFI44,
IFI6, and OAS2). While kinetically similar to infected cells, adja-
cent cells regulated fewer (about half) antiviral genes, with only
a handful being uniquely regulated. To demonstrate that fluctua-
tions in the array data were not due to cDNA library defects, beta
actin expression in mock, HCV, and adjacent cells was
compared to two differentially regulated ISGs, IFIT1 and CCL5
(Figure 2G). Unlike beta actin, IFIT1 was upregulated in HCV-in-
fected and adjacent cells compared to mock. In contrast, signif-
icant upregulation of CCL5 was only observed in HCV-infected
cells (Figure 2G). These observations were confirmed by qPCR
(Figure 2H). Taken together, these data define donor-indepen-
dent, distinct, and dynamic antiviral responses in HCV-infected
and adjacent PHH, information that would have been impossible
to obtain without this LCM-driven transcriptomic approach.
Host Responses Associated with More Effective
Antiviral Control
Despite infecting PHH with the same virus inoculum and proto-
col, we observed significant donor-to-donor variation in HCVMicrobe 15, 190–202, February 12, 2014 ª2014 Elsevier Inc. 191
(legend on next page)
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sponses dominated, we hypothesized that gene signatures
associated with more effective antiviral control would emerge
from comparing donors with disparate infection frequencies.
We created two groups: high donors and low donors, each
comprised of the three donors with the highest and lowest infec-
tion frequencies based on the following criteria. Low donors had
the lowest infection frequencies on 1 dpi and/or the lowest fre-
quencies on 3 dpi, while high donors had the highest frequencies
on 1 dpi and/or 3 dpi (Figures 3A and 4B). An inverse relationship
is seen when comparing the two groups (Figure 3A) with respect
to the number of significantly regulated genes (Figure 3B).
Despite a significantly higher infection frequency at 1 dpi, high
donors regulated only about half as many genes as low donors
(Figure 3B). The number of antiviral genes upregulated in low do-
nors exceeded that of high donors in both number and percent-
age (Figure 3C), indicating that a more robust antiviral response
might be determining differences in infection frequency.
Ingenuity gene ontology analyses defined the responses asso-
ciated with more effective viral control. Compared to high
donors, the antiviral response in low donors was increased in
magnitude and complexity with inducers of the innate immune
response (DDX58, TRIM25, STAT1, etc.) and 14 other antiviral
genes uniquely upregulated (Figure 3D). Additionally, low donors
showed unique regulation of 10 antiviral genes in adjacent cells,
whereas high donors uniquely regulated none. These data are
consistent with the idea that more robust antiviral responses in
adjacent cells may limit cell permissiveness to virus infection
and spread. Pathway analysis predicted the functional conse-
quences of the transcriptional response (Figure 3E). The biolog-
ical function RNA virus replication was among the top five most
significantly affected functions associated with low donors. The
associated Z score, a predictor of functional effect, suggested
that the suite of associated genes would reduce RNA virus
replication to a greater degree than those associated with high
donors. Thus, the virologic, transcriptomic, and bioinformatic
data converge, defining responses associated with lower infec-
tion frequency and more effective viral control.
Linkage of IFNL Variation to PHH Infection Frequency
and Host Response
SNPs at or near the IFNL3 (interleukin-28B [IL-28B]) locus (e.g.,
rs12979860) strongly associate with HCV clearance and treat-
ment response, but the underlying mechanisms responsible
remain unclear (Ge et al., 2009; Naggie et al., 2012; Thomas
et al., 2009; Urban et al., 2010). More recently, polymorphisms
at an IFN lambda locus, IFNL4, were shown to have similar pre-
dictive value, thus galvanizing the importance of IFNL in HCV
infection (Figure 4A) (Prokunina-Olsson et al., 2013). We geno-Figure 1. Isolation of HCV-Infected PHHs via LCM
(A) The HCV-dependent fluorescence relocalization (HDFR) reporter. Phase cont
HCV. Filled arrowhead, HDFR nuclear-translocated HCV-infected cells. Empty a
(B) Schematic of laser capture microdissection (LCM). The collection surface is s
(C) Schematic of the capture of mock, HCV-infected, and adjacent cells.
(D) Schematic of the workflow from LCM to array.
(E) LCM of mock, HCV-infected, and adjacent cells chronicled in a stepwise fash
(F) Quantitative RT-PCR for HCV genomes in LCM sample lysate. Each dot repre
point (days postinfection, dpi) is indicated in the gray box. Asterisks indicate statis
Cell Host &typed all of our donor cells (n = 22) and confirmed the strong link-
age disequilibrium (Prokunina-Olsson et al., 2013) between
IFNL3 and IFNL4 SNPs, with zygosity of major and minor
IFNL3 and IFNL4 alleles in perfect agreement (Figure 4B).
To examine the importance of the IFNL locus on HCV infection
outcome in PHH, we stratified our data by IFNL genotype. Signif-
icantlymore cells were infected in donors with unfavorable geno-
types (minor alleles) as compared to favorable genotypes (major
alleles) (Figure 5A; p < 0.05). While examining genotype-specific
host responses, we observed that the numbers of significantly
regulated genes increased stepwise from homozygous major
(favorable) to homozygous minor (unfavorable) alleles in both
HCV-infected and adjacent cells (Figure 5B). People with unfa-
vorable genotypes chronically infected with HCV typically have
higher baseline levels of ISGs (Urban et al., 2010). We observed
a similar trend with the highest absolute number of regulated
antiviral genes seen in minor allele donors (Figures 5C and 5E).
In contrast, the fraction of the total response dedicated to the
antiviral response among homozygous donors was the highest
in major allele donors (Figure 5C; IFNL3 T/T: HCV 32%, ADJ
15% versus IFNL3 C/C: HCV 41%, ADJ 49%). In pathway ana-
lyses similar to those in Figure 3E, ‘‘viral infection’’ was among
the top three most significantly affected biological functions.
Even though minor allele donors regulated more genes within
this pathway (number of regulated genes per condition: HCV
C/C = 22, HCV T/T = 38, ADJ C/C = 14, ADJ T/T = 43), the Z
scores predicted a similar negative effect on viral infection
(Z scores: HCV C/C = 3.6, HCV T/T = 4.3, ADJ C/C = 3.3,
ADJ T/T = 3.7) (Figure 5D). Additionally, IFNL major allele
donors regulated fewer cellular pathways in addition to the anti-
viral response as compared to minor allele donors, thus demon-
strating that major allele donor responses were predominantly
antiviral and more focused (Figure S6).
To gain a better understanding of the host responses unique to
homozygous IFNL alleles, we performed ingenuity pathway anal-
ysis (IPA) on genes unique to each genotype. The top network
associated with the 32 genes unique to HCV-infected cells of
major allele donors was cell death and survival, while the antimi-
crobial response led in minor allele donors (Figure 5E). Of the
genes shared between genotypes, the antiviral program was
dominant in both HCV-infected (69%) and adjacent (72%) cells.
The numbers of significantly regulated antiviral genes unique to
minor allele donors (HCV, 13; ADJ, 15) exceeded that of major
allele donors (HCV, 8; ADJ, 3) (Figure 5E), but when expressed
as a fraction of the overall host response, this trendwas reversed
(HCV C/C 25%, T/T 16%; ADJ C/C 20%, T/T 9%) (Figure 5E).
While the magnitude of antiviral gene induction was for the
most part similar, six genes (IFI6, IFIT1, IFIT2, IFIT3, OAS1, and
RSAD2) in minor allele donors were upregulated more thanrast (left) and fluorescent (right) images of HDFR expressing PHH infected with
rrowhead, HDFR nontranslocated adjacent cells.
ticky for the slide membrane, facilitating capture upon cutting.
ion from left to right.
sents the average value per 10 cells. The number of donors (donor n) per time
tical significance as determined by ANOVA (p < 0.001). See also Figures S1–S4.
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Figure 2. Systems Virology Reveals Unique Signatures Associated with HCV-Infected and Adjacent Cells
(A) HCV infectious virus production in PHHs (left). Cells were infected at a similar moi. Titers in culture supernatants were determined by TCID50 (donor n: 1, 3
dpi = 19, 7 dpi = 17). Each time point represents the 24 hr accumulation of virus. The dashed line indicates the limit of detection. HCV infection frequency is shown
(right). Each dot represents the average infection frequency per donor (donor n: 1, 3 dpi = 22, 7 dpi = 20).
(B) The numbers of significantly regulated genes (ANOVA, Benjamini Hochberg MTC, FDR 0.05, fold change cutoff of 2) in HCV infected and adjacent cells.
Donor n per time point: 8 (1 dpi), 3 (3 dpi) and 4 (7 dpi).
(C) The numbers of antiviral response genes induced in HCV infected and adjacent cells.
(D) Microarray data for the IFNL1 gene.
(E) IFNL1 secreted in culture supernatants from donors 4720, 5679, 5728, 5123, 5686, and 3868. Select cultures were treated with HCV replication
inhibitor 20CMA.
(F) The temporal order of the antiviral response in HCV-infected and adjacent cells (ADJ). The absence of a colored box indicates that fold change did not exceed
the 2-fold cutoff.
(legend continued on next page)
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the IFNL genotype stratified and low infection frequency donor
array data to explore the relationship between IFNL genotype
and the signatures of more effective viral control (Figures 3 and
5G). The numbers of overlapping genes were similar in HCV-
infected and adjacent cells (Figure 5G), but genes related to
cell death (e.g., MLKL) were enriched among low/major allele
donors, while those unique to minor allele donors were largely
ISGs (Figure 5H). To examine if there were inherent IFNL geno-
type-dependent differences in the naive cells, we compared
the transcriptomes of mock-infected cells from each IFNL3
genotype (i.e., C/C versus T/T, C/C versus C/T, and C/T versus
T/T). While housekeeping gene expression was consistent,
genes related to cell death were enriched in major allele donors
(Figure 5I). More than half of the uniquely regulated genes in
major allele donors were related to cell death, raising the
possibility that these cells may be poised to activate the cell
death/antiviral program even before virus infection (Figure 5J).
Thus, our data demonstrate a clear correlation between IFNL
genotype, hepatocyte permissiveness, the focus of the host
response, and induction of innate antiviral immunity.
Stochasticity of the Host Response Is Associated with
Host Genotype and Infection Frequency
In our previous array analyses analyzed by ANOVA, each
quadruplicate sample was averaged for each gene, and if the
variation was excessive the data were discarded. Thus, biologi-
cally significant data could be missed in the pursuit of statistical
significance. Figure 6 displays the viral load and host response in
each quadruplicate sample of 20 mock, HCV, or adjacent cells
for each donor profiled on 1 dpi, organized from left to right
with decreasing infection frequency. Similar to the data in Fig-
ure 1F, HDFR-positive cells were enriched for HCV genomes
as compared tomock and adjacent cells (Figure 6A). The expres-
sion of beta actin via microarray or qRT-PCR was found to be
uniform for each donor, suggesting that fluctuations in genes
of interest were not due to random sample variation (Figure 6B).
No correlation was observed between the levels of HCV RNA
and ISG expression (IFIT1, CCL5, and BST2) on a per sample
basis. Importantly, the ISG array data for each sample were
confirmed by qRT-PCR (Figure 6C). We then investigated the
relationship between donor infection frequency and ISG expres-
sion in each LCM sample. In contrast to lower infection fre-
quency donors, high infection frequency donors (4728, HFTR)
failed to consistently upregulate IFIT1 in HCV-infected and adja-
cent cells (Figure 6C). For lower infection frequency donors,
CCL5 expression was fairly uniform in HCV-infected cells but
intermittent in adjacent cells, a trend not observed in high infec-
tion frequency donors (Figure 6C). Similarly, qRT-PCRmeasure-
ment of BST2 gene expression in HCV-infected and adjacent
cells was more common in lower infection frequency donors.
Together, these data demonstrate that (1) ISG expression can
be compartmentalized (e.g., CCL5) in specific populations
(HCV-infected cells) within a complex mixture, (2) the uniformity(G) Example expression data on 1 dpi.
(H) Confirmation of example array data by qPCR of cDNA libraries.
Asterisks indicated statistical significance as determined by ANOVA (p < 0.001 f
represent the range. See also Figure S5.
Cell Host &of ISG gene expression in HCV-infected and adjacent cells varies
from donor to donor, and (3) the uniformity of ISG expression
correlates with the level of infection frequency.
Given the IFNL-dependent effects observed on infection fre-
quency (Figure 5A), we further explored the relationship between
host genetics, the host response, and the outcome of infection.
IFNL genotype and ethnicity can synergize to create an unfavor-
able treatment prognosis (e.g., IFNL3 T/T, African decent). Alter-
natively, ethnicity can antagonize unfavorable IFNL status and
relieve some of its negative effects, suggesting that clinical phe-
notypes can also be driven by genetic factors independent of
IFNL status (Naggie et al., 2012). The gene SLC45A2 has been
under heavy positive selection in populations evolving in Europe,
and SNPs at the locus can be used to assess ethnicity (Sabeti
et al., 2007). While we have few donors for a given genotype,
we observed trends similar to those seen clinically (Figures 4B
and 6C). The four donors with the highest infection frequency
were homozygous or heterozygous for clinically unfavorable
IFNL alleles and the SLC45A2 African heritage SNP. Two of the
four donors with the lowest infection frequency were homozy-
gous (3868) or heterozygous (5123) for clinically unfavorable
IFNL alleles, but their likely European decent (SLC45A2, Euro-
pean SNP) may have offset the negative effects associated
with IFNL genotype. Lastly, the remaining donors with the lowest
infection frequency were homozygous for favorable IFNL alleles
(5780; 5763). Collectively, these data demonstrate that hepato-
cytes from donors with IFNL minor alleles are more likely to be
infected and exhibit a less robust and intermittent antiviral
response as compared to cells from major allele donors.
DISCUSSION
Studying HCV in its native environment, the human hepatocyte,
is technically challenging. Low infection frequencies, low levels
of viral antigen, and high autofluorescence are a few of the
challenges that have prevented the identification, isolation, and
transcriptional profiling of HCV-infected cells in vivo. HCV infec-
tion is most often diagnosed during the chronic phase. Hence,
we lack an understanding of the early responses in the human
liver during the first few days of acute infection. This void has
been addressed to some extent by experimental infection of
chimpanzees (Bigger et al., 2001, 2004; Su et al., 2002). Similar
to our data, the antiviral response (i.e., IFI6, IFIT1, IFITM1,
ISG15, MX1, etc.) dominates at early times (2 dpi) in the livers
of chimpanzees destined to resolve acute HCV infection (Bigger
et al., 2001, 2004). However the origin of this signature, whether
from infected hepatocytes, noninfected hepatocytes, nonparen-
chymal cells, or inflammatory cells, is not clear. This is unlikely to
be addressed in the future, given the new restrictions on chim-
panzee research (Kaiser, 2013) and the inability to obtain human
liver samples during early acute infection. Despite this, systems
biology approaches such as the one described here can provide
a unique and unbiased insight into the initial battle between virus
and host.or A, B, D, and G; p < 0.05 for E) or t test (H). Error bars in (D), (E), (G), and (H)
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Figure 3. Host Responses Associated with More Effective Viral Control
(A) Infection frequency in high (donors 4728, HFTR, and 5737) and low (donors 5123, 5780, 5763) infection frequency donors. Each dot represents the average
infection frequency per donor. Asterisks indicate statistical significance as determined by t test (p < 0.005).
(B) Significantly regulated genes in HCV-infected and adjacent cells at 1 dpi.
(C) Antiviral response genes in HCV-infected and adjacent cells at 1 dpi.
(D) Venn diagram comparing all significantly regulated genes or antiviral response genes for HCV-infected and adjacent cells and heatmap of antiviral response
genes. White boxes indicate that the gene did not exceed the 2-fold change cutoff.
(E) IPA for the biological function RNA virus replication. Thelog(p value) (orange bars) measures the statistical strength of the submitted gene list. The numbers
of associated genes are listed above each bar. The Z score (purple bars) predicts the functional effect of the gene list. Negative Z scores indicate a reduction in
function. ADJ refers to adjacent cells throughout.
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HCV pathogenesis, but the challenges that complicate in vivo
studies (i.e., low infection frequency, low levels of viral antigen,
etc.) are also encountered with PHHs (Andrus et al., 2011; Mar-
ukian et al., 2011; Ploss et al., 2010). By coupling anHCV-depen-
dent fluorescent cellular reporter with LCM, we successfully196 Cell Host & Microbe 15, 190–202, February 12, 2014 ª2014 Elseisolated and transcriptionally profiled HCV-infected PHHs. In-
duction of the innate antiviral program was the hallmark of the
early host response to HCV in PHHs. Our data stand in stark
contrast to those gleaned from the profiling of HCV-infected can-
cer cell lines where cell cycle, apoptosis, oxidative stress, lipid
metabolism, and, to a lesser extent, host defense were chieflyvier Inc.
Figure 4. IFNL3, IFNL4, and SLC45A2 Geno-
type Data for All Donors
(A) Description of the major and minor alleles for
interferon lambda 3 (IFNL3) and 4 (IFNL4).
(B) IFNL3, IFNL4, and SLC45A2 genotype data for
all donors and their relation to infection frequency.
Polymorphisms in SLC45A2 (solute carrier family
45, member 2, SNP rs16891982) can predict Euro-
peanorAfrican ethnicity. Af, African; Eur, European.
Infection frequency classification is based on the
infection frequency foreachdonorat1dpiand3dpi.
For example, low donors had the lowest infection
frequency at 1 dpi and/or 3 dpi. See also Table S1.
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hepatoma cell lines used for these studies have multiple func-
tional abnormalities (Li et al., 2005; Sainz et al., 2009), the dra-
matic differences with PHHs are not surprising and highlight
the dangers of extrapolating data derived from commonly used
cancer cell lines to initial virus and host interactions in vivo.
Rather, our data are reminiscent of the transcriptional profile of
HCV-infected PHHs reported by Thomas et al., where the induc-
tion of a subset of antiviral genes (IFIT1, CXCL10, IFI44L, CCL5,
etc.) was observed, but the contribution of infected or bystander
cells to this response was not determined (Thomas et al., 2012).
In contrast, we were able to measure the transcriptional
response in uniformly infected PHHs over time, thus defining
transcriptional response kinetics at very early times after infec-
tion. In addition, we determined the gene signatures associated
with more effective antiviral control through the comparison of
responses from donors with high and low infection frequencies.
Althoughmany of the genes associated with antiviral response in
low infection frequency donors have been reported to have anti-
HCV activities (Schoggins et al., 2011), a number of others repre-
sent potential anti-HCV genes.
HCV pathogenesis is a complex process, the outcome of
which is affected by viral genotype, host genetics, innate and
adaptive immunity, and communication among hepatocytes
and nonparenchymal cells. For decades, prevailing dogma
posited that HCV chronicity is driven, at least in part, by the ability
of the virus to successfully antagonize or inactivate various innate
antiviral defenses (Horner and Gale, 2013). Here, we demon-
strate that HCV is able to complete its replication cycle in cells
with competent innate immunity, with an antiviral program
induced in infected cells of almost every donor tested. These
data suggest that HCV does not necessarily have to completely
suppress innate immunity to establish chronic infection; sup-
pression just long enough to produce progeny capable of infect-
ing another target cell may be sufficient. Another explanation, yet
to be tested in PHHs, is that HCV may not need to block innate
immune transcriptional responses, but rather evades antiviral
effectors at the level of translation. In this scenario, supported
by studies in hepatoma cells, HCV alters the infected cell by acti-
vating PKR and imposing a selective block on translation of anti-
viral gene transcripts (Garaigorta and Chisari, 2009).
In addition to viral effects, host genetics play a significant role
in the establishment of chronic infection. Host variation in the
IFNL locus is associated with spontaneous clearance of HCV
and type I IFN-based treatment success (Ge et al., 2009; Thomas
et al., 2009). Although the underlying mechanisms determiningCell Host &these IFNL-dependent, clinical outcomes remain unknown, our
results are consistent with two non-mutually exclusive hypothe-
ses: (1) donors with clinically favorable genotypes have height-
ened ability to respond to infection or (2) donors with clinically
favorable genotypes are able to generate more effective antiviral
responses. We observed a significant enrichment in cell death-
related genes in cells from donors with IFNL major alleles.
Recent clinical studies report a higher basal ISG expression in
noninfected livers of patients with IFNL3 major alleles (Raglow
et al., 2013), and chronically infected major allele patients exhibit
increased liver necroinflammation and poorer clinical outcomes
as compared to patients with minor alleles (Noureddin et al.,
2013). Taken together, these data collectively suggest that innate
genotype-dependent differences could make hepatocytes more
poised to respond to infection through activation of cell death
and/or antiviral programs. The recent discovery of IFNL4 has pro-
vided insight into the effect of host genetics on the quality of the
host response toHCV. IFNL4gene expression is intricately linked
to a specificmutation (TT/-G, rs368234815), andminor alleles are
strongly associated with poor clinical outcomes in HCV-infected
patients (Bibert et al., 2013; Prokunina-Olsson et al., 2013). IFNL4
expression is thought to increase basal ISG expression and
induce an IFN refractory state, thus decreasing the efficacy of
IFN treatment (Prokunina-Olsson et al., 2013). However, this
has not been conclusively demonstrated. Similar to these clinical
observations, we observed a correlation between IFNL (both
IFNL3 and IFNL4) genotype, HCV infection frequency, and the
quality of the antiviral response. This convergence reinforces
the utility of our in vitro model for studying aspects of HCV path-
ogenesis relevant to those seen on the organismal level. As
compared to minor allele donors, we show that PHHs from
donors with major IFNL alleles have a more focused and uniform
antiviral response, especially within nonproductively infected
adjacent cells. Communication between HCV-infected and adja-
cent cells of major allele donors may trigger a more robust innate
response, limiting viral spread. Alternatively, adjacent cells may
represent a population that has encountered virus, mounted
effective control, and aborted productive infection. In contrast,
the less focused, more sporadic host antiviral response of IFNL
minor allele donors suggests a pervasive dysregulation or
response deficit.
Given the complexities of studying hepatotropic infectious dis-
eases in humans, in vitro cultures of PHHs serve to bridge the
gap between the laboratory and the clinic. While PHHs are argu-
ably the most biologically and clinically relevant in vitro system
by which to study liver biology, the cells from each donor areMicrobe 15, 190–202, February 12, 2014 ª2014 Elsevier Inc. 197
Figure 5. Genetic Variation in IFNL Is Associated with Increased HCV Infection Frequency and Distinct Host Responses
(A) Infection frequency for each IFNL3 (rs12979860) genotype. Each dot represents the average frequency per donor. Statistical significance was determined by
ANOVA (p < 0.05).
(B) Significantly regulated genes on 1 dpi. Donor n: IFNL3 C/C = 2, C/T = 4, T/T = 2.
(legend continued on next page)
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IFN Lambda Alleles Predict HCV Permissivenessgenetically unique. Rather than shudder and recoil from host
genetic variability, it should be embraced. These data highlight
the power and utility of studying viral infections in PHHs of dispa-
rate genetic backgrounds and reveal a remarkable convergence
with clinical findings. Overall, our study suggests that early virus-
host interactions, in particular host genetics and the induction of
innate antiviral immunity, play a critical role in determining the
outcome of HCV infection. Further work using PHH donors of
disparate genetic backgrounds will continue to provide unique
insights into the effect of host genetics on HCV infection but
should also serve as a fruitful approach for the study of other clin-
ically important human hepatotropic pathogens, such as hepati-
tis B virus (HBV), hepatitis A virus (HAV), hepatitis E virus (HEV),
yellow fever virus, and malaria.
EXPERIMENTAL PROCEDURES
Human Subjects
All protocols involving the use of human tissue were reviewed and exempted
by the Rockefeller University Institutional Review Board.
Generation of HCVcc
Cell culture-derived HCV (HCVcc) for a genotype 2a recombinant J6JFH
Clone2 (HCV Clone 2) was generated through electroporation of a human hep-
atoma cell line, Huh-7.5, with in vitro transcribed HCV genomic RNA as
described (Marukian et al., 2008; Walters et al., 2009). HCVcc stocks were
collected in serum-free media containing Dulbecco’s modified Eagle’s
medium (DMEM), 0.15% BSA (Fraction V, Sigma), penicillin/streptomycin
(Gibco), 0.1mM nonessential amino acids (Gibco), and 20mMHEPES (Gibco),
concentrated 25-fold (Amicon Ultracel 100K), and stored at 80C. Mock-
transfected control supernatants were generated by electroporation of Huh-
7.5 cells in the absence of RNA and treated similarly to those of HCVcc.
Isolation and Culture of Enriched Human Fetal Hepatocytes
Coded fetal livers (17–20 weeks gestation) were procured through Advanced
Bioscience Resources (ABR) or the Human Fetal Tissue Repository of the
Albert Einstein College of Medicine (AECOM). Enriched primary human fetal
hepatocyte cultures (PHHs) were prepared as previously described (Andrus
et al., 2011). PHHs were seeded on collagen-coated multiwell plates (BD
BioCoat) or collagen-coated (0.01% calf, Sigma) polyethylene napthalate
(PEN) LCM slides (Molecular Machines and Industries) at 50,000–100,000
cells/cm2 in William’s E medium (Gibco) supplemented with 10% fetal bovine
serum (FBS) (HyClone), 2mML-glutamine (Invitrogen), 13 ITS Plus (BDBiosci-
ences), and antibiotics. At 24 hr after plating, cells were washed with William’s
E medium and then maintained in Hepatocyte Defined Medium (HDM; BD
Biosciences) with medium exchanges every other day.
HCV Live-Cell Reporter
Tomonitor HCV infection in live cells, lentivirus expressing an HCV-dependent
fluorescence relocalization (HDFR) reporter was employed (Jones et al., 2010;
Marukian et al., 2011; Ploss et al., 2010). Lentiviral pseudotyped particles (PPs)
were created and stored as described (Jones et al., 2010; Marukian et al.,
2011). PHHs were transduced with PPs 1 day after plating as described(C) Antiviral response genes on 1 dpi. The percentage of the overall host respon
(D) Predictive biological functional analysis for viral infection. The log(p value) (o
associated genes are listed above each bar. The Z score (purple bars) predicts
function.
(E) Venn diagram of significantly regulated genes and antiviral response genes fo
(F) Heatmap displaying the antiviral gene expression for unique and shared gene
(G) Venn diagram comparing gene expression data for low infection frequency, C
(H) Expression heatmap for genes shared between low infection frequency donor
marked in the boxes below.
(I) Microarray data for housekeeping and select cell death genes. Statistical sign
(J) Relative expression of cell death-related genes in mock cells from IFNL3 C/C
Cell Host &(Andrus et al., 2011). At 48 hr after transduction and just prior to HCV infection,
70%–90% of cells expressed HDFR in all donors.
Infection of PHHs with HCVcc, Quantitation of Infectious Virus, and
Viral Genomes
At 3 days after PHH plating, culture medium was removed, and HCVcc or
mock-transfected supernatants were added at a multiplicity of infection
(moi) of 10–12. After 6 hr at 37C, virus was removed, cultures were rinsed
5–8 times with William’s E, and HDM was added. To monitor infectious virus
production after infection, culture medium was harvested and monolayers
were thoroughly rinsed (3–6 times) to reduce infectious virus to background
levels. Virus titer in culture supernatants was determined by 50% tissue culture
infectious dose (TCID50) assay in Huh-7.5 cells (Lindenbach et al., 2005). To
measure infection frequency, the total number of HDFR-positive cells was
divided by the total number of transduced cells in photographs of 3–5 random
203 objective fields. Imageswere scored, and select images were blinded and
confirmed by a second person. To demonstrate that HDFR translocation is
dependent on virus replication, a replicase inhibitor, 20-C-methyladenosine
(20CMA, 2 mM), or vehicle (DMSO) was added 2 hr prior to HCV infection and
then maintained during and after infection. HCV genomic RNA in LCM sample
lysate or extracted total cellular RNA (QIAGEN RNeasy) was quantitated via
qRT-PCR (EraGen MultiCode-RTx, EraGen Biosciences) with primers against
the 30 UTR and a synthetic RNA standard to determine genome copy number.
Laser Capture Microdissection of HCV-Infected Primary Human
Hepatocytes
HCV or mock-infected LCM slides were rinsed extensively to remove virus
from the culture surface, fixed with 100% ethanol (EtOH), and immediately
used for LCMon theMMI CellCut system (Molecular Machines and Industries).
For each donor, 30 cells of the following populations were captured in quadru-
plicate: mock-infected cells (perinuclear RFP) from mock-infected slides,
HCV-infected cells (nuclear RFP) from HCV-infected slides, and cells adjacent
(adjacent cells) to HCV-infected cells (perinuclear RFP) from HCV-infected
slides. Adjacent cells were between 0 and 10 cell body widths away from an
HCV-infected cell (nuclear RFP). For documentation of the process, digital
photos were taken throughout. Each population was collected in a separate
tube and placed on ice until LCM was completed. Cells were directly lysed
on the capture surface with 3 ml of Direct Lysis Buffer (NuGEN) stored at
80C until processing.
Transcriptome Amplification and Microarray Analysis
The transcriptome of each captured population was linearly amplified using
OneDirect (NuGEN) according to protocol. For each amplification, a no-tem-
plate control (lysis buffer) and a positive control (250 pg Universal Human
Reference RNA, Agilent Technologies) were included. The cDNA generated
via the no-template control did not produce a measureable signal via microar-
ray. Amplified products were biotin labeled (NuGEN, Encore BiotinIL Module)
and hybridized (48C) to Illumina Whole-Genome Expression BeadChips
(Illumina, HumanHT-12 V4 0 R2) according to protocol. Similar lots of microar-
ray chips were used for each donor. Array data were analyzed using
GeneSpring 11. Significantly regulated genes were determined by ANOVA,
with a Benjamini-Hochberg multiple testing correction (MTC) and a false dis-
covery rate (FDR) of 5%, comparing HCV-infected or adjacent cells to a
time-matched mock. Only genes with a fold change greater than 2-fold over
mock were considered for analysis. IPA software was employed to determinese dedicated to the antiviral program is indicated in the white box.
range bars) measures the statistical strength of each gene list. The numbers of
the functional effect of the gene list. Negative Z scores indicate a reduction in
r IFNL3 C/C and T/T genotypes.
s from (E).
/C, and T/T donors.
s and C/C or T/T donors. Cell death-related genes (purple) and ISGs (gray) are
ificance was determined by ANOVA.
donors (ANOVA). ADJ refers to adjacent cells throughout. See also Figure S6.
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Figure 6. Stochasticity of the Host Response Is Associated with Host Genotype and Infection Frequency
Data for each quadruplicate LCM sample per group (mock, HCV, adjacent) per donor is depicted in each panel. The IFNL3 and SLC45A2 genotypes for each
donor are indicated by the color of each header. Genotype abbreviations are described in Figure 4. The donors are ordered from left to right with decreasing
infection frequency.
(A) Quantitation of HCV genomes by qRT-PCR in LCM sample lysate from 10 cells.
(B andC)Microarray (red circles, left y axis) and qPCR confirmation of array data (black open circles, right y axis) for the house keeping gene and beta actin (B) and
three interferon-stimulated genes, IFIT1, CCL5, and BST2 (C).
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to which genes associated with a given function were fulfilled by the submitted
list was determined in Ingenuity (log[p value]). The functional effect of the
submitted gene list was determined by the IPA Z score algorithm. Negative
Z scores indicate a reduction in function. A gene list comprised of 538 genes
titled antiviral genes was created by merging Ingenuity’s antiviral response,
interferon signaling, and activation of IRF by cytosolic pattern recognition re-
ceptor lists with the ISG list reported in Schoggins et al. (2011).
To confirm the trends seen in the microarray data, relative gene expres-
sion in OneDirect cDNA libraries was determined by SYBR Green qPCR200 Cell Host & Microbe 15, 190–202, February 12, 2014 ª2014 Else(Applied Biosystems) on a Roche 480 LightCycler. With the exception of
beta actin (ACTB), primers were designed for all genes using the Roche
Assay Design Center (Table S2). Expression levels were normalized to a
housekeeping gene, beta actin, and donor and time-matched mock-infected
samples using the comparative Ct method developed by Schmittgen and
Livak (2008).
IFNL1 ELISA
IFNL1 secretion was measured in select donors (4720, 5679, 4278, 5123,
5686, 3868) via ELISA (eBioscience). Cultures were either mock infected orvier Inc.
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IFN Lambda Alleles Predict HCV Permissivenessinfected with HCV in the presence or absence of 20CMA as described above.
Culture supernatants representing a 24 hr accumulation of IFNL1 were har-
vested on the indicated days and stored at 80C until analysis.
Donor Genotyping
DNA was extracted from cell pellets using QIAGEN DNeasy Blood and Tissue
Kit or TRIzol (Invitrogen). For IFNL3 (rs12979860) genotyping, a 145 bp
amplicon was generated using primers F-GCCTGTCGTGTACTGAACCA and
R-GGCTCAGGGTCAATCACAG. For SLC45A2 (rs16891982) genotyping,
PCR was performed using primers F-ACCCACTGATTCCAAGAGCA and
R-CCTCAACAGCCTCCAATCTC. For IFNL4 (rs368234815), PCR was per-
formed using F-GAACGGGTGTATGGGAACC and R- GCCTGCTGCAGAAG
CAGAGAT. All amplicons were directly sequenced to determine genotype.
Statistical Analysis
Statistical analysis of virological data was performed with GraphPad Prism 4.
Specific tests are noted in figure legends.
ACCESSION NUMBERS
The NCBI GEO accession number for the microarray data reported in this
paper is GSE54648.
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